Q4 and full year 2025 earnings presentation Making Life Better Forward-looking statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to expectations of Ingersoll Rand Inc. (the "Company" or "Ingersoll Rand") regarding the performance of its business, its financial results, its liquidity and capital resources and other non-historical statements. These forward-looking statements generally are ...

Company Overview - Ingersoll Rand is a global company with a revenue of $7.5 billion, an EBITDA margin of 27%, and a free cash flow margin of approximately 17% [4] - The company's market capitalization is $34 billion [4] - Since its IPO of Gardner Denver in 2017 and the acquisition of Ingersoll Rand in 2020, the total shareholder return has exceeded 330% [4] Life Science Technologies Platform - The presentation at the JPMorgan Healthcare Conference marks the first time Ingersoll Rand is presenting at this prestigious event [2] - The CEO, Vicente Reynal, emphasized the importance of the Life Science platform, which will be further detailed by Scott Watson, SVP and General Manager [2]

Core Insights - The article emphasizes the importance for investors to identify industrial companies that have experienced negative analyst revisions to their earnings estimates as earnings season approaches [2] Company Analysis - Companies like Ingersoll Rand Inc. are highlighted as examples of those facing negative EPS revisions, which may indicate concerns regarding their near-term performance [2]

Financial Performance - Q3 2025 orders increased by 8%, while revenue increased by 5%[13] - Adjusted EBITDA increased by 2%, but the adjusted EBITDA margin decreased by 70 bps[13] - Adjusted EPS increased by 2% year-over-year[13] - Free cash flow was approximately flat year-over-year[17] - Total available liquidity was $3.8 billion, including $1.2 billion in cash and cash equivalents and $2.6 billion available from the revolving credit facility[17] Segment Performance - Industrial Technologies & Services revenue increased by 5%, with organic growth declining by 2.1%[21] - Precision & Science Technologies revenue increased by 5.3%, with organic growth of 1.7%[28] - Precision & Science Technologies adjusted EBITDA margin increased by 80 bps year over year[28] M&A Activity - Year-to-date, the company closed 14 transactions[11] - Expected annualized inorganic revenue acquired is approximately $250 million[11] - The company expects to acquire 400-500 bps of annualized inorganic revenue in 2025[11] Full-Year 2025 Guidance - Total revenue is expected to grow by 4-6%[31] - Organic revenue is expected to decline by 2% to 0%[31] - Adjusted EBITDA is projected to be $2.06 billion - $2.09 billion, representing a 2-4% year-over-year increase[31] - Adjusted EPS is expected to be $3.25 - $3.31, representing a (1%) - +1% year-over-year change[31]